Evidence map›Paper›PMID 42306928›Full record

ReviewACS applied bio materials2026

Advances in Biomaterial-Based Cardiac Organoids Engineering for Modeling Development and Congenital Heart Defects.

Yuanhui Song, Yashi Li, Nhu Y Mai, Huiyao Liu, Ava Hong, Era Jain, Huaxiao Yang, Xinrui Wang, Zhen Ma

Abstract readReview
In one paragraph

Review in ACS applied bio materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuanhui SongDepartment of Biomedical & Chemical Engineering, Syracuse University, Syracuse, New York 13244, United States.
Yashi LiDepartment of Biomedical & Chemical Engineering, Syracuse University, Syracuse, New York 13244, United States.
Nhu Y MaiDepartment of Biomedical & Chemical Engineering, Syracuse University, Syracuse, New York 13244, United States.ORCID 0000-0003-0604-9078
Huiyao LiuDepartment of Biomedical & Chemical Engineering, Syracuse University, Syracuse, New York 13244, United States.
Ava HongDepartment of Biomedical Engineering, University of North Texas, Denton, Texas 76203, United States.
Era JainDepartment of Biomedical & Chemical Engineering, Syracuse University, Syracuse, New York 13244, United States.ORCID 0000-0002-7172-401X
Huaxiao YangDepartment of Biomedical Engineering, University of North Texas, Denton, Texas 76203, United States.
Xinrui WangDepartment of Pharmacology, Upstate Medical University, Syracuse, New York 13210, United States.
Zhen MaDepartment of Biomedical & Chemical Engineering, Syracuse University, Syracuse, New York 13244, United States.ORCID 0000-0001-5228-105X

Funding

Establishing an In Vitro Embryotoxicity Risk Classification System Based on Human Cardiac Organoid ModelR01HD101130 · NICHD · SYRACUSE UNIVERSITY · PI MA, ZHEN · 2020 to 2025
$2.3M
NOTCH signaling on the underdeveloped cardiac vascularization of hypoplastic left heart syndrome in the hiPSC-derived vascularized cardiac organoidsR15HD108720 · NICHD · UNIVERSITY OF NORTH TEXAS · PI YANG, HUAXIAO · 2022 to 2022
$438k
American Heart Association-American Stroke Association 24IVPHA1288417 - ZHEN MANICHD NIH HHS R01 HD101130NICHD NIH HHS R15 HD108720
6 · The paper itself

Abstract

Human cardiac organoids have emerged as transformative platforms that bridge the gap between reductionist 2D cultures and poorly predictive animal models. By recapitulating the three-dimensional tissue architecture, multicellular composition, and developmental dynamics of the human heart, these systems enable mechanistic studies of heart development and congenital heart disease. This review surveys the bioengineering strategies underlying cardiac organoid generation, with an emphasis on how biomaterial-based approaches enhance organoid fidelity, functional maturation, and experimental reproducibility. We discuss how specific material platforms, spanning Matrigel encapsulation, natural and decellularized extracellular matrix hydrogels, and synthetic polymer networks, translate defined mechanical, biochemical, and structural cues into functional advances in vascularization, cardiomyocyte maturation, and scalable organoid production. A comparative framework is provided across all platform types to guide material selection for cardiac organoid culture and engineering. Applications of biomaterial-supported cardiac organoids in modeling human cardiogenesis and congenital heart defects, as well as in developmental cardiotoxicity screening, are reviewed in depth. Furthermore, we discuss persistent challenges in organoid maturation, vascularization, and standardization and outline future directions integrating advanced biomaterials, organ-on-chip systems, and artificial intelligence-driven analytics to enable next-generation human cardiac models.

Indexed as

Biocompatible MaterialsHeartHeart Defects, CongenitalOrganoidsTissue EngineeringAnimalsHumansHydrogelsBiocompatible MaterialsHydrogelsbiomaterialscardiac organoidscardioidscardiovascular diseasedisease modeling

Identifiers

PMID42306928
PMCPMC13670163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.